A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Potwierdzony rozpoznaniem zaawansowanego raka płuca (stadium 4) typu non-small cell
- •Nie otrzymywał wcześniej leków systemowych na raka płuca w zaawansowanym stadium
- •Ma mierzalne ognisko nowotworu widoczne w badaniach obrazowych
- •Dobry stan zdrowia ogólny (0-1 w skali ECOG)
- •Dostępny materiał z guza do badania na obecność białka PD-L1
- •Nie ma przeciwwskazań do stosowania pembrolizumabu i chemioterapii
✗ Disqualifies
- •Nowotwór zawiera elementy małokomórkowego raka płuca
- •Aktualnie uczestniczy w innym badaniu klinicznym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Southern Cancer Center, P.C.
Daphne, United States
Los Angeles Cancer Network
Glendale, United States
Rocky Mountain Cancer Centers, LLP
Pueblo, United States
NYU Langone Hospital Long Island
Mineola, United States
NYU Langone Hospital Manhattan
New York, United States
White Plains Hospital
White Plains, United States
Blue Ridge Cancer Center
Blacksburg, United States
Virginia Cancer Specialists, PC
Fairfax, United States
Shenandoah Oncology P.C.
Winchester, United States
Institut Catala D'Oncologia de Girona
Girona, Spain
Trial contact
Elelta Shiferraw
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.